Lethal effect of complement and lysozyme on polymyxin-treated, serum-resistant gram-negative bacilli.
When genetically serum-resistant Escherichia coli, Klebsiella pneumoniae, and Citrobacter freundii, but not Pseudomonas aeruginosa or Proteus mirabilis, were exposed to polymyxin B, they became susceptible to the bactericidal action of normal human and rabbit sera. In constrast, beta-lactam and aminoglycoside antibiotics did not render any serum-resistant bacteria serum-sensitive. Synergy between polymyxin B and the serum bactericidal system could be demonstrated by the addition of polymyxin B to bacteria in vitro, as well as to bacilli in serum from rabbits injected with the antibiotic. Polymyxin B-treated bacteria were killed by normal, lysozyme-depleted, C2-deficient, and hypogammaglobulinemic sera, but not by heated or C6-deficient sera. These findings indicate that polymyxin B-treated bacteria can be killed via the alternative complement pathway. However, C3 and C3b were detected on the surface of serum-resistant E. coli, regardless of whether the bacteria had been treated with polymyxin B. This observation suggests that a change in susceptibility to the alternative complement pathway was not the only explanation for the acquired serum sensitivity. Polymyxin B may also affect a step in the complement sequence beyond the activation of C3, a step that is apparently blocked in serum-resistant gram-negative bacteria.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001770:Blood Bactericidal Activity; D002954:Citrobacter / Q000187:drug effects / Q000276:immunology; D003167:Complement Activation; D003176:Complement C3 / Q000276:immunology; D003179:Complement C3b / Q000276:immunology; D003170:Complement Pathway, Alternative; D003165:Complement System Proteins / Q000276:immunology*; D004755:Enterobacteriaceae / Q000187:drug effects*; D004926:Escherichia coli / Q000187:drug effects / Q000276:immunology; D006801:Humans; D066298:In Vitro Techniques; D007711:Klebsiella pneumoniae / Q000187:drug effects / Q000276:immunology; D009113:Muramidase / Q000276:immunology*; D011112:Polymyxin B / Q000494:pharmacology*; D011113:Polymyxins / Q000494:pharmacology*; D011817:Rabbits
D000900:Anti-Bacterial Agents; D003176:Complement C3; D011113:Polymyxins; D003179:Complement C3b; D003165:Complement System Proteins; D009113:Muramidase; D011112:Polymyxin B